Enrique Gallardo

4.8k total citations
90 papers, 1.6k citations indexed

About

Enrique Gallardo is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Enrique Gallardo has authored 90 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Pulmonary and Respiratory Medicine, 32 papers in Oncology and 26 papers in Surgery. Recurrent topics in Enrique Gallardo's work include Prostate Cancer Treatment and Research (24 papers), Bladder and Urothelial Cancer Treatments (22 papers) and Renal cell carcinoma treatment (20 papers). Enrique Gallardo is often cited by papers focused on Prostate Cancer Treatment and Research (24 papers), Bladder and Urothelial Cancer Treatments (22 papers) and Renal cell carcinoma treatment (20 papers). Enrique Gallardo collaborates with scholars based in Spain, United States and Chile. Enrique Gallardo's co-authors include Joaquim Bellmunt, Joan Carles, Begoña Mellado, Vicente Guillém, Juan J. de la Cruz, José Baselga, Albert Font, Daniel Castellano, Aranzazu González del Alba and Luis Paz‐Ares and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Enrique Gallardo

82 papers receiving 1.5k citations

Peers

Countries citing papers authored by Enrique Gallardo

Since Specialization

Citations

This map shows the geographic impact of Enrique Gallardo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Enrique Gallardo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Enrique Gallardo more than expected).

Fields of papers citing papers by Enrique Gallardo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Enrique Gallardo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Enrique Gallardo. The network helps show where Enrique Gallardo may publish in the future.

Co-authorship network of co-authors of Enrique Gallardo

This figure shows the co-authorship network connecting the top 25 collaborators of Enrique Gallardo. A scholar is included among the top collaborators of Enrique Gallardo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Enrique Gallardo. Enrique Gallardo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Therapeutic Alliances for Optimizing the Management of Patients with Prostate Cancer: SOGUG Multidisciplinary Expert Panel Recommendations 2025 ·Cancers ·Aranzazu González del Alba, (unknown), José Ángel Arranz, Enrique Gallardo, Regina Gironés Sarrió, Fernando López‐Campos, (unknown), María José Méndez-Vidal, Alfonso Gómez‐Iturriaga	0
2	Catheter – related thrombosis in cancer patients: Data from the registry of thrombosis and nEoplasia of SEOM (TESEO) 2024 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), Dialina Brilhante, (unknown), (unknown), Eva Martínez de Castro, José Muñoz-Langa, Elena Vázquez, (unknown), (unknown), Enrique Gallardo, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Paula Jiménez‐Fonseca, Andrés J. Muñoz Martín	0
3	A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1 2024 ·Clinical Cancer Research ·Neeraj Agarwal, Daniel Castellano, Teresa Alonso‐Gordoa, Jóse Ángel Arranz Arija, Émeline Colomba, Gwénaëlle Gravis, Loı̈c Mourey, Stéphane Oudard, Aude Fléchon, (unknown), Pablo Maroto, Michael T. Schweizer, Enrique Gallardo, (unknown), Arjun Vasant Balar, Nadine Haddad, Adams K. Appiah, (unknown), Josep M. Piulats	6
4	POS1315 IMMUNE CHECKPOINT INHIBITOR-RELATED MYOSITIS. CASE REPORTS AND LITERATURE REVIEW 2024 ·Annals of the Rheumatic Diseases ·(unknown), (unknown), (unknown), (unknown), Enrique Gallardo, (unknown), Jordi Gratacós, (unknown)	0
5	EORTC 2238 “De-Escalate”: a pragmatic trial to revisit intermittent androgen deprivation therapy in the era of new androgen receptor pathway inhibitors 2024 ·Frontiers in Oncology ·(unknown), Fabio Turco, Saskia Litière, Béatrice Fournier, Anna Patrikidou, Enrique Gallardo, Ray McDermott, (unknown), Silke Gillessen, Bertrand Tombal	8
6	SEOM clinical guidelines for the treatment of advanced prostate cancer (2020) 2021 ·Clinical & Translational Oncology ·Aranzazu González del Alba, María José Méndez-Vidal, (unknown), Elena Castro, José A. Martínez-Climent, Enrique Gallardo, Enrique González‐Billalabeitia, David Lorente, Pablo Maroto, (unknown)	21
7	639P 223Ra in asymptomatic patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who progressed to first-line abiraterone acetate or enzalutamide 2020 ·Annals of Oncology ·Joan Carles, Teresa Alonso, B. Mellado González, M.J. Méndez Vidal, (unknown), Aranzazu González del Alba, Josep M. Piulats, (unknown), Enrique Gallardo, Rafael Morales‐Barrera, Pilar Paredes, Òscar Reig, (unknown), (unknown), Teresa Bonfill, Cristina Suárez, Andrea Malfettone, J. Garde	1
8	Consensus statement of the Spanish Society of Internal Medicine and the Spanish Society of Medical Oncology on secondary thromboprophylaxis in patients with cancer 2020 ·Clinical & Translational Oncology ·T. Quintanar, Carme Font, Enrique Gallardo, Raquel Barba, Berta Obispo, Carmen Díaz‐Pedroche	1
9	SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019) 2020 ·Clinical & Translational Oncology ·Andrés J. Muñoz Martín, Enrique Gallardo, Ignacio Escobar, (unknown), Virginia Martínez-Marín, (unknown), Pedro Pérez Segura, T. Quintanar, Mercedes Salgado Fernández	32
10	Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era 2019 ·European Urology Oncology ·Joaquim Bellmunt, Emilio Esteban, (unknown), Juan Manuel Sepúlveda-Sánchez, Pablo Maroto, Enrique Gallardo, Aranzazu González del Alba, (unknown), Marta Guix, J.L. González-Larriba, José Ángel Arranz, Miriam Redrado, Alfonso Calvo	5
11	Phase 2 Randomized Study of Radiation Therapy and 3-Year Androgen Deprivation With or Without Concurrent Weekly Docetaxel in High-Risk Localized Prostate Cancer Patients 2018 ·International Journal of Radiation OncologyBiologyPhysics ·Joan Carles, Enrique Gallardo, Montserrat Domènech, Albert Font, Joaquim Bellmunt, (unknown), Begoña Mellado, M.I. Sáez, Cristina Suárez, María José Méndez, Pablo Maroto, Raquel Luque, (unknown), (unknown), Teresa Bonfill, Rafael Morales‐Barrera, José Ángel García, (unknown), Xavier Maldonado, P. Foro	5
12	Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma 2018 ·BMC Pharmacology and Toxicology ·María José Méndez-Vidal, (unknown), Urbano Anido, Isabel Chirivella, (unknown), E. Fernández-Parra, Marta Guix, Carolina Hernández, J. Lambea, A. Montesa, Álvaro Pinto, (unknown), Enrique Gallardo	20
13	New advances in genitourinary cancer: evidence gathered in 2014 2015 ·Cancer and Metastasis Reviews ·Cristina Suárez, Javier Puente, Enrique Gallardo, María José Méndez-Vidal, José A. Martínez-Climent, Luis León‐Mateos, David Olmos, Xavier García del Muro, Enrique González‐Billalabeitia, Enrique Grande, Joaquim Bellmunt, Begoña Mellado, Pablo Maroto, Aranzazu González del Alba	4
14	Expert opinion on first-line therapy in the treatment of castration-resistant prostate cancer 2015 ·Critical Reviews in Oncology/Hematology ·Pablo Maroto, Eduardo Solsona, Enrique Gallardo, Begoña Mellado, Juan Moróte, José Ángel Arranz, F. Gómez-Veiga, Miguel Unda, Miguel Ángel Climent, Antonio Alcaraz	13
15	Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer 2014 ·Molecular Cancer Therapeutics ·Mercedes Marín‐Aguilera, Jordi Codony‐Servat, Òscar Reig, Juan José Lozano, Pedro L. Fernández, (unknown), Natàlia Jiménez, Michael Donovan, Pere Puig, Lourdes Mengual, Raquel Bermudo, Albert Font, Enrique Gallardo, María J. Ribal, Antonio Alcaraz, Pere Gascón, Begoña Mellado	123
16	Synchronous versus metachronous brain metastasis from testicular germ cell tumors (TGCT): an analysis from the Spanish Germ Cell Cancer Group data base 2014 ·Clinical & Translational Oncology ·(unknown), Regina Gironés, Jorge Aparicio, (unknown), J. R. Germa-Lluch, Xavier García del Muro, Sergio Vázquez‐Estévez, A. Sáenz, Javier Sastre, (unknown), Enrique Gallardo, Enrique González‐Billalabeitia, (unknown), Josefa Terrasa, (unknown), Carmen Santander, (unknown), (unknown), (unknown), Marta López Brea, Pablo Maroto	15
17	Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity 2011 ·Annals of Oncology ·Joaquim Bellmunt, J.L. González-Larriba, Celia Prior, Pablo Maroto, Joan Carles, Daniel Castellano, Begoña Mellado, Enrique Gallardo, José Luis Perez‐Gracia, (unknown), (unknown), Joan Albanell, Alfonso Calvo	101
18	Concurrent hyperfractionated radiotherapy and chemotherapy for patients with limited small-cell lung cancer. Results from a single institution 2009 ·Reports of Practical Oncology & Radiotherapy ·(unknown), (unknown), (unknown), (unknown), (unknown), Enrique Gallardo, (unknown), (unknown), (unknown)	2
19	Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer 2009 ·British Journal of Cancer ·Begoña Mellado, Albert Font, Antonio Alcaraz, Luís Antón Aparicio, (unknown), (unknown), Enrique Gallardo, (unknown), (unknown), (unknown), Pedro L. Fernández, Pere Gascón	39
20	Oral contraceptives containing desogestrel in the maintenance of the remission of hirsutism: Monthly versus bimonthly treatment 1991 ·Contraception ·(unknown), Enrique Gallardo	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact